How China plans to ‘firmly rank at the global forefront’ with 25% of first-in-class drugs
China has set its sights on becoming a global biomedicine powerhouse by 2030, targeting key technological breakthroughs and at least a quarter of the world’s first-in-class drugs market under a new five-year plan for the sector. By the end of the decade, China would “firmly rank at the global forefront” in biopharmaceutical research and development and applications, with its “core…
China has unveiled an ambitious five-year plan aimed at solidifying its position as a global leader in biomedicine by 2030. The government's strategy outlines critical milestones, targeting at least 25 percent of the world's first-in-class drugs market and promoting the biomedical industry as a "pillar industry" for the nation. By the end of the decade, China aims to "firmly rank at the global forefront" in biopharmaceutical research and development, with core competitiveness and international influence significantly enhanced.
The plan, jointly published by eight government agencies, sets 10 measurable targets, including pharmaceutical enterprises generating combined revenue of no less than 3.5 trillion yuan and the country producing drug makers with annual revenue exceeding 10 billion yuan. The biomedical industry is projected to grow at an annual rate of more than 20 percent by 2030, with a substantial number of cutting-edge innovations emerging from Chinese-developed first-in-class drugs.
Written by urgent.news from SCMP Business's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
